MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$4,640,000
Net Income
-$43,012,000
Net Profit Margin
-926.98%
EPS
-$0.13
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Collaboration revenue - related party
4,640,000
-
0
0
Research and development
30,721,000
32,003,000
28,632,000
31,164,000
General and administrative
20,839,000
14,089,000
13,772,000
13,737,000
Impairment of long-lived assets
0
-
0
0
Total operating expenses
51,560,000
46,092,000
42,404,000
44,901,000
Loss from operations
-46,920,000
-46,092,000
-42,404,000
-44,901,000
Interest and other income, net
4,647,000
3,573,000
3,660,000
3,926,000
Interest expense
343,000
300,000
313,000
344,000
Other income (expenses), net
-61,000
212,000
247,000
-81,000
Total other income (expenses), net
4,243,000
3,485,000
3,594,000
3,501,000
Loss before income taxes
-
-
-38,810,000*
-
Tax benefit at federal statutory rate
-
-
-10,021,500*
-
Research tax credits
-
-
445,750*
-
Change in valuation allowance
-
-
8,853,500*
-
Stock-based compensation
-
-
1,570,000*
-
Other
-
-
43,750*
-
Other adjustments
-
-
0*
-
Income tax expense
-
-
0*
-
Net loss
-42,677,000
-42,607,000
-38,810,000
-41,400,000
Net unrealized gain (loss) on available-for-sale investments
-335,000
-452,000
34,000
280,000
Net comprehensive loss
-43,012,000
-43,059,000
-38,776,000
-41,120,000
Basic EPS
-0.13
-0.18
-0.171
-0.19
Diluted EPS
-0.13
-0.18
-0.171
-0.19
Basic Average Shares
328,930,269
240,290,782
226,163,829
222,038,680
Diluted Average Shares
328,930,269
240,290,782
226,163,829
222,038,680
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net comprehensive
loss
-$43,012,000
(15.71%↑ Y/Y)
Interest and other
income, net
$4,647,000
(-24.89%↓ Y/Y)
Net loss
-$42,677,000
(16.23%↑ Y/Y)
Net unrealized gain
(loss) on...
-$335,000
(-280.68%↓ Y/Y)
Total other income
(expenses), net
$4,243,000
(-27.79%↓ Y/Y)
Interest expense
$343,000
(27.99%↑ Y/Y)
Other income
(expenses), net
-$61,000
(-41.86%↓ Y/Y)
Loss from operations
-$46,920,000
(17.42%↑ Y/Y)
Collaboration revenue -
related party
$4,640,000
Total operating
expenses
$51,560,000
(-9.26%↓ Y/Y)
Research and development
$30,721,000
(-23.50%↓ Y/Y)
General and
administrative
$20,839,000
(45.92%↑ Y/Y)
Buy us a coffee
Allogene Therapeutics, Inc. (ALLO)
Allogene Therapeutics, Inc. (ALLO)